OR WAIT null SECS
Jonathan Alicea is an assistant editor for HCPLive. He graduated from Princeton University with a degree with English and minors in Linguistics and Theater. He spends his free time writing plays, playing PlayStation, enjoying the company of his 2 pugs, and navigating a right-handed world as a lefty. You can email him at email@example.com.
Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.
A new year means assessing how far the field of dermatology has come in terms of its therapeutic options and offerings.
Recent years have seen new and emerging therapies for a variety of conditions. For example, the FDA has approved dupilumab—a biologic—for use in atopic dermatitis. Research has also suggested great potential for JAK inhibitors—such as ritlecitinib for vitiligo, abrocitinib for atopic dermatitis, and deucravacitinib for psoriasis.
In this episode of Derm Discussions, Brad Glick, DO, talked with Todd Schlesinger, MD, Dermatology & Laser Center of Charleston, SC, about the newest therapeutic agents within the dermatologist toolbox.
Schlesinger is a board-certified dermatology and dermasurgeon who has committed himself to various types of research and development. His experience also extends to inflammatory dermatoses as well as new technologies, especially as they relate to laser and light-based therapies.
For this episode, he offered strategies on practical ways to manage dermatological diseases, pointing to the current and supporting literature and research. He covered various therapeutic classes—from biologics to the novel JAK inhibitors—for conditions such as atopic dermatitis, melanoma, plaque psoriasis, and alopecia areata.
Schlesinger spoke on new and ongoing research, which promises further advancements in the field, and agents that should be on every dermatologists’ radar.
As this derm discussion proves, there is certainly plenty of ground to cover in the realm of dermatology-related therapies.